263 filings
Page 5 of 14
6-K
j2n vcexn
10 Sep 20
ESSA Pharma to Participate in Multiple Upcoming Investor Conferences
9:10am
S-8
qr9h5xel4r fs4sz
13 Aug 20
Registration of securities for employees
12:00am
6-K
myx62 kxiu4
7 Aug 20
Current report (foreign)
12:00am
6-K
qfcbdzlvt57 ng4
6 Aug 20
Current report (foreign)
12:19pm
6-K
yo43f
31 Jul 20
Current report (foreign)
10:35am
424B5
yb0r oqqq7hosfr
29 Jul 20
Prospectus supplement for primary offering
9:55pm
6-K
x983z6
28 Jul 20
ESSA Pharma Announces Pricing of Public Offering of Common Shares
9:48pm
6-K
h1rb0pvbr6
28 Jul 20
ESSA Pharma Announces Proposed Public Offering of Common Shares
4:24pm
424B5
rxq7g
28 Jul 20
Prospectus supplement for primary offering
4:11pm
6-K
o3vv5da
15 Jul 20
ESSA Pharma Announces First Patient Dosed in a Phase 1 Clinical Trial of EPI-7386 for Metastatic Castration-Resistant Prostrate Cancer
8:33am
S-8
ldm2f92hj5nb3jm
29 Jun 20
Registration of securities for employees
12:00am
6-K
0u6zwbfa7gj
22 Jun 20
ESSA Pharma Presents Therapeutic Potential of EPI-7386 at the 2020 American Association for Cancer Research Virtual Annual Meeting II
9:17am
6-K
ut6o4hisv 280kn
27 May 20
ESSA Pharma to Present at Jefferies Virtual Healthcare Conference
8:37am
6-K
twg5b412sf5a3
15 May 20
ESSA Pharma Presents Therapeutic Potential of EPI-7386 at 2020 Virtual American Urological Association (AUA) Annual Meeting
8:34am
6-K
f2463l
7 May 20
Current report (foreign)
5:31pm
6-K
a560g
1 May 20
ESSA Pharma Announces FDA Allowance of the Clinical Investigation of EPI-7386 in Prostate Cancer
12:00am
6-K
mcdw7d0o 2o
15 Apr 20
Current report (foreign)
5:04pm
6-K
28y6vu07
14 Apr 20
Open Market Sale Agreementsm
12:00am
6-K
8bmcc opkyt
14 Apr 20
ESSA Pharma Enters into At-The-Market Equity Offering Sales Agreement
12:00am
424B5
ly4ujgwd70 v1k7wkepr
13 Apr 20
Prospectus supplement for primary offering
5:01pm